Pseudomonas aeruginosa – an environmental bacteria that can cause devastating multidrug-resistant infections, particularly in people with underlying lung conditions – evolved rapidly and then spread globally over the last 200 years, probably driven by changes in human behaviour, a new study has found.
A major new institute opens today, bringing together the largest concentration of scientists and clinicians in heart and lung medicine in Europe.
Scientists have been able to track how a multi-drug resistant organism is able to evolve and spread widely among cystic fibrosis patients – showing that it can evolve rapidly within an individual during chronic infection.
World-leading AI technology developed by the Cambridge Centre for AI in Medicine and their colleagues – some of which is being showcased this week at the North American Cystic Fibrosis Conference 2020 – offers a glimpse of the future of precision medicine, and unprecedented predictive power to clinicians caring for individuals with the life-limiting condition.
Chris Skidmore, Minister for Universities, Science, Research and Innovation, announced on 10 July 2019 a £30 million award to the University of Cambridge to support the new Cambridge Heart and Lung Research Institute (HLRI).
Almost 30 years on from the discovery of the genetic defect that causes cystic fibrosis, treatment options are still limited and growing antibiotic resistance presents a grave threat. Now, a team of researchers from across Cambridge, in a major new centre supported by the Cystic Fibrosis Trust, hopes to turn fortunes around.
A multi-drug resistant infection that can cause life-threatening illness in people with cystic fibrosis (CF) and can spread from patient to patient has spread globally and is becoming increasingly virulent, according to new research published today in the journal Science.
An experimental cystic fibrosis drug has been shown to prevent the disease’s damage to the liver, thanks to a world-first where scientists grew mini bile ducts in the lab.
Scientists at the University of Cambridge have successfully created ‘mini-lungs’ using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs for this debilitating lung disease.
New discoveries by Cambridge scientists about a molecular waste-disposal process that ‘eats’ bacteria are influencing the clinical management of cystic fibrosis, and could be the basis of innovative new treatments to fight off bacteria.
© 2025 University of Cambridge